The recent discovery of bacterial receptors such as NOD2 that contribute to crosstalk between innate and adaptive immune systems in the digestive tract constitutes an important challenge in our understanding of liver injury mechanisms. The present study focuses on NOD2 functions during liver injury. NOD2, TNF-a and IFN-g mRNA were quantified using real-time PCR in liver samples from patients and mice with liver injury. We evaluated the susceptibility of concanavalin A (ConA) challenge in NOD2-deficient mice (Nod2 À/À ) compared to wild-type littermates. We tested the effect of muramyl dipeptide (MDP), the specific activator of NOD2, on ConA-induced liver injury in C57BL/6 mice. We studied the cellular distribution and the role of NOD2 in immune cells and hepatocytes. We demonstrated that NOD2, TNF-a and IFN-g were upregulated during liver injury in mice and humans. Nod2 À/À mice were resistant to ConA-induced hepatitis compared to their wild-type littermates, through reduced IFN-g production by immune cells. Conversely, administration of MDP exacerbated ConA-induced liver injury. MDP was a strong inducer of IFN-g in freshly isolated human PBMC, splenocytes and hepatocytes. Our study supports the hypothesis that NOD2 contributes to liver injury via a regulatory mechanism affecting immune cells infiltrating the liver and hepatocytes. Taken together, our results indicate that NOD2 may represent a new therapeutic target in liver diseases.
Liver injury is associated with elevated bacterial translocation related to an intestinal phenomenon designated 'leaky gut'. The latter contributes to a rise in bacterial cell wall products, also called pathogen-associated molecular patterns (PAMP), in portal tracts. 1 PAMP may enhance inflammatory processes within the liver through their interaction with pathogen recognition receptors. It has recently been suggested that peptidoglycan, a cell wall product common to both Grampositive and Gram-negative bacteria, may be an important inducer of the proinflammatory process in the digestive tract. 2, 3 NOD2 is a new cytosolic pathogen recognition receptors, which functions at the crossroads of innate and adaptive immune responses. It has been reported to contribute to the proinflammatory process of intestinal disorders such as Crohn's disease. 4 NOD2, encoded by the CARD15 gene, is expressed in immune cells such as monocytes/macrophages, T lymphocytes, granulocytes, dendritic cells and also in colon epithelial cells. [5] [6] [7] This receptor is the specific sensor for muramyl dipeptide (MDP), a frequently described immunostimulatory peptidoglycan motif common to all bacteria. 3, 8, 9 MDP recognition by NOD2 leads to activation of nuclear factor-kB and induces proinflammatory cytokine production by immune cells through a Rip-like interactive clarp kinase-dependent signaling pathway. 6, 10 Interestingly, TNF-a can also induce NOD2 expression via a consensus site for NF-kB contained in its promoter. 11 Since NOD2 regulates the inflammatory process in the digestive tract, we hypothesized that it may also play a pivotal role in regulation of liver injury.
In the present study, we demonstrate for the first time that: (1) NOD2 expression is upregulated during liver injury in mice and humans; (2) NOD2-deficient mice (Nod2 À/À ) are resistant to concanavalin A (ConA)-induced hepatitis compared to their wild-type littermates, through reduced IFN-g production by immune cells; (3) administration of MDP, the specific activator of NOD2, exacerbates ConA-induced liver injury; and (4) MDP is a potent inducer of cytokines in freshly isolated peripheral blood mononuclear cells (PBMC), splenocytes and hepatocytes. Taken together, these results strongly indicate that NOD2 is involved in regulation of liver injury and could represent a new therapeutic target in liver diseases.
MATERIALS AND METHODS Tissue Samples and Cells
In vitro, NOD2 expression was evaluated in isolated human hepatocytes and PBMC. NOD2 regulation in mice was evaluated in both ConA (10 mg/kg)-and LPS (10 mg)-induced liver injuries. Livers were removed 2, 4, 8, 12 and 24 h after retro-orbital ConA administration, and 1, 2, 4, 6, 12 and 24 h after intraperitoneal LPS injection. Human livers were obtained from control patients undergoing tumor resection without liver disease (n ¼ 15). Inflamed livers were taken from patients with autoimmune hepatitis (n ¼ 5). Hepatocytes were isolated from control livers of patients using the perfusion/collagenase method. 12 All patients had given informed consent and the project was approved by the ethical committee of Lille Hospital.
Detection and Quantification of NOD2 and Cytokine mRNA Levels Real-time PCR analyses were performed for quantification of NOD2, TNF-a, IFN-g mRNA expression (Table 1) . TATA box-binding protein and b-actin were used as housekeeping genes. 13 Sequence-specific PCR primers were designed using primer Express Software version 1.5 (Applied Biosystems, Foster City, CA, USA; see Table 1 for details). One microgram of RNA was retro-transcribed using Superscript s (Invitrogen, Cergy-Pontoise, France) following the manufacturer's recommendations. Quantification of cDNA was performed using ABI Prism 7000 (Applied Biosystems, Foster City, CA, USA). Mouse and human NOD2 PCR products were sequenced using ABI Prism 377 XL (Applied Biosystems, Foster City, CA, USA) and were compared to the reference NM_145857 and NM_022162.
NOD2 and CD68 Staining by Immunofluorescence Microscopy
For NOD2 immunostaining, we used three different antibodies (one monoclonal and two polyclonal) directed against either the leucine-rich repeats (LRR) region 14, 15 or the caspase recruitment domain of NOD2 (Cayman Chemical, Ann Arbor, MI, USA). The three antibodies gave similar results. NOD2 immunostainings presented in the different figures were performed with an antibody from Cayman Chemical. Livers were fixed in paraformaldehyde (PFA) 4% and embedded in paraffin. Four-micrometer-thick sections were exposed to primary antibodies directed against NOD2 (dilution 1:50) and then to Alexa-488-conjugated secondary antibody for 1 h (dilution 1:100). Negative controls were incubated with rabbit serum instead of specific antibody, or with specific antibody preincubated with an excess of recombinant NOD2-LRR protein. Immunofluorescence was revealed under a fluorescence microscope (Leica, Bensheim, Germany). Immune mononuclear cells were identified with CD68. NOD2-CD68 double-staining was performed by adding one step to the protocol of NOD2 staining described above and analyzed with confocal microscopy.
Study of the Susceptibility of Nod2-Deficient Mice to ConA-Induced Hepatitis C57BL/6 background Nod2 knockout mice (Nod2 À/À ) were generated in the laboratory of M Giovannini. 16 The first Nod2 coding exon was deleted, resulting in a null Nod2 allele. Germline-transmitting chimeras were crossed with C57BL/6 mice to generate Nod2 þ /À mice. After ten backcrosses with C57BL/6 mice, Nod2 þ /À mice were intercrossed to generate À/À mice. Liver sections were incubated overnight with a primary rat monoclonal antibody directed against IFN-g (dilution 1:100, Interchim, Montluçon, France). Negative controls consisted of omission of the first antibody and use of an irrelevant antibody. Eight hours after ConA injection, NF-kB activity was assessed by evaluation of IkBa degradation using western blot.
Role of MDP in ConA-Induced Liver Injury
Muramyl dipeptide, the specific activator of Nod2, has been purchased from Sigma Chemical (Sigma-Aldrich Chimie, Lyon, France). The MDP purity has been tested by HPLC (98% of purity). The specificity of MDP for Nod2 has been previously reported by Girardin and coll. 9 Eight-week-old C57BL/6 mice were injected with 10 mg/kg of ConA. Just after ConA injection, eight mice received an i.p. injection of MDP (100 mg/kg) and eight mice received saline instead of MDP in two independent experiments. As controls, five mice 
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received only saline and five mice received saline instead of ConA and MDP. Blood was collected and livers were harvested 24 h after ConA injection. ALT and AST were measured in the sera of mice using the standard photometric method (Hitashi 747 analyzer). One part of the liver was fixed in paraformaldehyde 4% and paraffin-embedded for histological analysis and another part was frozen for RNA studies.

Role of MDP in IFN-c Production in Hepatic Cells and Splenocytes
Human PBMC and hepatocytes were isolated and cultured. These cells were pretreated or not for 24 h with TNF-a (50 ng/ml) and IFN-g (100 ng/ml) and then exposed to MDP (1 mg/ml) for 6 or 9 h. Two independent experiments were performed in triplicate. Splenocytes from mice were isolated by disruption of spleen in PBS containing bovine serum albumin and EDTA. After washing, cells were counted and plated in a six-well plate using RPMI medium. Splenocytes were cultured for 16 h with or without 1 mg/ml of MDP and harvested for IFNg mRNA quantification by real-time PCR.
Statistics
Data were expressed as mean ± s.e.m. or mean ± s.d. Statistical comparisons were performed using the Mann-Whitney test. A P-value o0.05 was considered as significant.
RESULTS
NOD2 Expression is Upregulated During Liver Injury in Mice and Humans
To investigate pathophysiological regulation of NOD2, we quantified TNF-a, IFN-g and NOD2 during a full time course of gene expression in response to LPS and ConA in mice. After intraperitoneal injection of LPS, livers displayed an expected increase in TNF-a mRNA, with a peak at 1 h and then a decrease, whereas IFN-g mRNA peaked at 4 h ( Figure 1a ). NOD2 mRNA kinetics showed sustained increased expression, with a biphasic curve containing a first peak at 1 h which paralleled TNF-a, and a second, weaker peak at 12 h (Figure 1a) . In ConA-induced hepatitis in mice, TNF-a and IFN-g mRNA levels peaked at 4 and 2 h respectively (Figure 1b) . NOD2 mRNA peaked at 2 h and remained stable from 2 to 12 h and then decreased progressively (Figure 1b) . Immunohistochemical results also argued in favor of upregulation of NOD2 protein expression in ConA-induced hepatitis (Figure 1c) . Moreover, in the human hepatocyte cell line HepG2, NOD2 mRNA expression was upregulated by TNF-a and IFN-g (Supplementary Figure 1) . This upregulation of NOD2 was synergized after stimulation with both TNF-a and IFN-g (Supplementary Figure 1) .
In human autoimmune hepatitis, which is a typical liver disease mediated by lymphocytes and driven by proinflammatory cytokines such as IFN-g, we observed significant hepatic induction of NOD2, TNF-a and IFN-g expression compared to control patients (Figure 1d ).
Mice Lacking Nod2 were Protected from ConA-Induced Hepatitis To further characterize the pathophysiological role of NOD2 in an experimental model of hepatitis, Nod2
À/À mice were challenged with ConA. Twenty-four hours after hepatitis induction, Nod2 À/À mice disclosed 86, 91 and 77% decreases in AST, ALT and LDH levels, respectively, compared to their wild-type littermates (Figure 2a) . Livers of ConA-treated wild-type mice showed diffuse necrosis in association with infiltration of mononuclear cells (Figure 2b ). In contrast, morphological alterations were milder, with only slight focal injury, in livers of ConA-injected Nod2 À/À mice. Furthermore, objective quantification of the necrotic surface by image analysis showed decrease in damaged areas in Nod2 À/À livers compared with Nod2 þ / þ livers (Figure 2c, 3 vs 13% respectively, Po0.001).
We analyzed the role of NOD2 during apoptosis induction in hepatocytes. In vivo, quantification of TUNEL-positive cells showed a decrease in hepatocyte apoptosis in Nod2 In addition, we examined hepatic expression of different cytokine mRNA levels in livers of Nod2 þ / þ and Nod2
ConA-injected mice. Significant reductions in IFN-g, mRNA levels (60%) were observed in Nod2 À/À mice compared to their wild-type littermates (Figure 3a , Po0.001). At the protein level, immunostaining of IFNg was lower in livers taken from Nod2 À/À mice than in those from Nod2 (Figure 3b , left panel), IFNg staining was mainly localized in injured areas surrounding infiltrating lymphocytes. In terms of mechanisms, 8 h after ConA injection, the livers of Nod2 À/À knockout mice displayed a 30% decrease in NF-kB activity compared to livers from wild-type mice (Figure 3c) .
Taken together, these data suggest that Nod2 À/À mice are resistant to ConA-induced hepatitis, and they support the role of NOD2 in regulation of hepatic injury, through IFN-g production by immune cells.
MDP Exacerbates ConA-Induced Liver Injury in Mice
To confirm that NOD2 regulates liver injury in a liganddependent manner, we showed that i.p. injection of MDP exacerbates ConA-induced liver injury, as indicated by: (a) a significant increase in AST/ALT (3.6-fold and 5-fold respectively, Figure 4a) and; (b) enlarged areas of necrosis and inflammation in livers compared to saline-treated mice ( Figure  4b) ; (c) increased levels of inflammatory cytokines TNF-a and IFN-g (3.2-fold and 2.8-fold respectively, Figure 4c ). In addition, NOD2 liver mRNA levels were induced in mice after i.p. injection of MDP (3.4-fold, Figure 4c ). As expected, MDP alone did not induce significant liver injury in wild-type mice according to AST/ALT levels (Figure 4a) . Moreover, MDP did not increase AST/ALT levels in liver of Nod2 À/À mice, contrary to what is observed in Nod2 (Figure 4d ).
Cellular Distribution and Role of NOD2 in IFN-c Production
To determine the cellular targets of MDP in promoting liver injury, we investigated NOD2 expression in different cell types present in the liver. Using real-time PCR, we showed that NOD2 expression was present in isolated human hepa- NOD2 and liver injury M Body-Malapel et al tocytes and at comparable levels in immune mononuclear cells such as PBMC (Figure 5a ). Confocal microscopy using an antibody directed against NOD2 and an antibody directed against CD68 showed that liver mononuclear cells as well as hepatocytes expressed NOD2 (Figure 5b ). To explore the role of NOD2 in immune cells, we demonstrated that MDP significantly induced IFN-g production by human PBMC after 6 and 9 h of stimulation with TNF-a and IFN-g (Figure 6a , P ¼ 0.05). To reinforce the ability of MDP to stimulate lymphocytes, one of the main cells involved in ConA-induced liver injury, we also showed that NOD2 activation upregulated IFN-g mRNA production in freshly isolated splenocytes stimulated with MDP ( Figure 6b, P ¼ 0.01) .
Finally, the effect of MDP on IFN-g production was explored in isolated human hepatocytes. In those cells pretreated with TNF-a and IFN-g, MDP significantly induced IFN-g production after 6 and 9 h of stimulation (P ¼ 0.028 and 0.026 respectively Figure 6c ).
DISCUSSION
The recent discovery of receptors for bacterial compounds such as NOD2, which contribute to regulation of proinflammatory cytokine production in the digestive tract, 17 constitutes an important challenge to our understanding of liver injury mechanisms. For the first time, we provide arguments that NOD2 is also implicated in liver injury.
The induction of NOD2 expression linked to cytokine production in different models of liver inflammation highlights similarities between intestinal cells and hepatocytes. This suggests common regulatory mechanisms involved in the innate immune response and its subsequent inflammation process in these two organs. Indeed, Rosenstiel et al 14 had previously demonstrated that TNF-a and IFN-g synergistically cooperate to induce Nod2 expression in intestinal epithelial cells. We confirmed the same phenomenon at the cellular level using a hepatocyte cell line. Both LPS and ConA lead to activation of the NF-kB pathway which is involved in cytokine production. 18, 19 NF-kB also induced NOD2 expression, which may explain at least in part the early peak following ConA and LPS challenge. 11 The sustained increase in Nod2 expression may be associated with a regulatory loop, with early activation by NF-kB followed by sustained stimulation, at least in part related to proinflammatory cytokines.
Direct evidence of the role of Nod2 in liver pathophysiology was provided by the resistance of Nod2 À/À mice in ConA-induced hepatitis. It is well established that liver injury is associated with increased intestinal permeability, a phenomenon designated 'leaky gut', and which contributes at least in part to the observed rise in bacterial cell wall products in the portal tracts. 1 This phenomenon has been demonstrated by the presence in the portal tract of entire bacterial pathogen products such as LPS at an early stage of liver injury. 20, 21 It is likely that small compounds such as MDP also cross the digestive barrier, but at an earlier stage. Nevertheless, the role of NOD2 acting through its ligand is confirmed by the exacerbation of ConA-induced liver injury after i.p. injection of MDP, the specific ligand of NOD2 and the absence of exacerbation of liver injury in Nod2 À/À mice that received MDP.
The description of NOD2 expression by both immune cells and hepatocytes has created ambiguity in terms of which cell compartment is relevant for Nod2 expression with respect to liver injury. The model of ConA-induced hepatitis is mainly driven by immune cells such as lymphocytes, and involves different mechanisms such as apoptosis, necrosis and production of inflammatory cytokines. 22, 23 Immune cells display higher levels of Nod2 than hepatocytes and are usually the main source of IFN-g during liver injury. 24 IFN-g together with other mediators are responsible for hepatocyte cell death. 25, 26 Our hypothesis is that Nod2 effects occur both in hepatocyte and immune cell compartments, with a probable major impact upon immune cells. The demonstration of the contribution of each compartment requires future studies bone marrow is deposited in wild-type mice, and using Nod2-specific deletion in hepatocyte compartments (AlbCre Â Nod2 flox/flox mice). An intriguing aspect of our study lies in the fact that Nod2, a sensor of PAMPs mainly implicated in innate immunity, drives liver injury related to immune cells involved in adaptive immunity. Such a role for Nod2 also exists in inflammatory bowel disease, 10 but has not been shown for other receptors of PAMPs such as TLR4 and CD14. Therefore, targeting of specific PAMPs might constitute an interesting approach depending on the potential mechanisms of liver injury. NOD2 antagonists might constitute potential candidates for limiting liver injury related to lymphocyte activation.
In conclusion, we provide the first evidence that NOD2 is a critical regulator of liver injury. The present study adds to our understanding of the pathogenesis of hepatic inflammation and rationalizes the performing of additional studies aimed at exploring this potential new target for treatment of liver injury.
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